Study to Assess the Safety and Tolerability after Multiple Oral Doses of AZD1656 in Patients with Type 2 Diabetes Mellitus Treated with Metformin

Study identifier:D1020C00019

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Single-Blind, Placebo-Controlled, Phase IIA Study to Assess the Safety and Tolerability after Multiple Oral Doses of AZD1656 in Patients with Type 2 Diabetes Mellitus Treated with Metformin

Medical condition

Type 2 Diabetes

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD1656, Placebo

Sex

All

Actual Enrollment

27

Study type

Interventional

Age

30 Years - 75 Years

Date

Study Start Date: 01 Jan 2009
Primary Completion Date: 01 Jul 2009
Study Completion Date: 01 Jul 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria